| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/19/2002 | WO2002072089A2 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof |
| 09/19/2002 | WO2002072085A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | WO2002072083A1 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 09/19/2002 | WO2002072073A2 Pharmaceutical formulation comprising atorvastatin calcium |
| 09/19/2002 | WO2002072031A2 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/19/2002 | WO2002072022A2 Substituted tetracycline compounds as antifungal agents |
| 09/19/2002 | WO2002072020A2 Novel anti-adhesive compounds and uses thereof |
| 09/19/2002 | WO2002072012A2 A novel proteosome-liposaccharide vaccine adjuvant |
| 09/19/2002 | WO2002072010A2 Taxane prodrugs |
| 09/19/2002 | WO2002072003A2 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | WO2002071874A2 Composition improving age-related physiological deficits and increasing longevity |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002059109A3 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases |
| 09/19/2002 | WO2002055663A3 Srebp pathway modulation through targeting hisrs |
| 09/19/2002 | WO2002053533A3 Kappa opioid receptor ligands |
| 09/19/2002 | WO2002050119A3 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 09/19/2002 | WO2002050070A3 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2002049624A3 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 09/19/2002 | WO2002036154A9 Procollagen (iii) propeptides and related substances for treating fibrotic diseases |
| 09/19/2002 | WO2002036106A3 Novel medicament compositions based on anticholinergics and corticosteroids |
| 09/19/2002 | WO2002033119A9 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002032940A3 Osteopontin-coated surfaces and methods of use |
| 09/19/2002 | WO2002026730A3 Fluorinated quinolones as antimitotic and antitumor agents |
| 09/19/2002 | WO2002024695A3 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 09/19/2002 | WO2002022871A3 Polymorphic bone morphogenetic protein 2 |
| 09/19/2002 | WO2002020841A3 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| 09/19/2002 | WO2002020018A8 Tablets containing epinastine manufactured by direct compression |
| 09/19/2002 | WO2002018553A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | WO2002018341A3 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 09/19/2002 | WO2002017949A9 Novel functions for dp214 |
| 09/19/2002 | WO2002014311A3 Urea compounds and methods of uses |
| 09/19/2002 | WO2002012456A3 Ampk-related serine/threonine kinase, designated snark |
| 09/19/2002 | WO2002010379A3 Modified cea and uses thereof |
| 09/19/2002 | WO2002005792A9 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 09/19/2002 | WO2002004487A3 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 09/19/2002 | WO2002002610A3 Secretion and trafficking molecules |
| 09/19/2002 | WO2001085956A3 Lipid metabolism enzymes |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | WO2001035899A9 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 09/19/2002 | WO2001030843A9 Ligand activated transcriptional regulator proteins |
| 09/19/2002 | WO2001019360A3 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| 09/19/2002 | WO2001007020A3 Carboxylic acid amides, medicaments containing these compounds and the use and production thereof |
| 09/19/2002 | US20020133835 Genetically engineering vertebrate germ cells; obtain gonads, incubate in transfection mixture and nucleotide sequences, transfect, recover transfected germ cells |
| 09/19/2002 | US20020133023 Antitumor agents, osteoporosis |
| 09/19/2002 | US20020133018 Calcium channel blockers; cardiovascular disorders; side effect reduction |
| 09/19/2002 | US20020133012 Therapy for neurokinin sensitive disease |
| 09/19/2002 | US20020133011 Alcoholism, psychological disorders |
| 09/19/2002 | US20020133010 Epoxidation; quaternization |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132978 VEGF-modulated genes and methods employing them |
| 09/19/2002 | US20020132973 Peptide parathyroid hormone analogs |
| 09/19/2002 | US20020132853 Diaryl piperazines and related compounds useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020132847 Inhibition of TNF-alpha-initiated neutrophil response |
| 09/19/2002 | US20020132844 Substituted pyrazole compounds useful for the treatment of mammalian infertility. |
| 09/19/2002 | US20020132842 Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them |
| 09/19/2002 | US20020132840 Treating angina in a mammal by administering an angiotensin II receptor antagonist. |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132828 N-substituted-4-(m-hydroxyphenyl)piperidine derivated and esters thereof, used to bind a kappa opioid receptor; treating drug addiction |
| 09/19/2002 | US20020132827 Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period." |
| 09/19/2002 | US20020132824 1,5-methylene-3-benzazepines used in treatment of neurological and psychological disorders,especially withdrawl from nicotine addiction |
| 09/19/2002 | US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/19/2002 | US20020132818 Thienopyrimidines |
| 09/19/2002 | US20020132814 AcrAB-like efflux pumps control resistance to drugs, even in highly resistant microbes; combination of an inhibitor of an AcrAB-like efflux pump and an antibiotic |
| 09/19/2002 | US20020132811 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| 09/19/2002 | US20020132810 Novel heterocyclic amide derivatives |
| 09/19/2002 | US20020132809 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 09/19/2002 | US20020132807 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 09/19/2002 | US20020132806 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X |
| 09/19/2002 | US20020132805 Containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts such as disodium EDTA; especially the antihistamines loratadine, descarboethoxyloratadine, and azatadine |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132778 Modulating angiogenesis |
| 09/19/2002 | US20020132777 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132773 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | US20020132754 Producing pharmaceuticals for improving perception, concentration, learning and/or memory. |
| 09/19/2002 | US20020132334 Nucleotide sequences coding preferential polypeptide for use in the treatment of tumors and nervous system disorders |
| 09/19/2002 | US20020132330 Polypeptide for use in the treatment, prevention and diagnosis of inflammation, cell proliferation and apoptosis |
| 09/19/2002 | US20020132319 Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132236 Specific inhibitors of ribosome recycling factors (RRF) |
| 09/19/2002 | US20020132018 Use of non-alkalized cocoa solids in a drink |
| 09/19/2002 | US20020132009 Entacapone, nitecapone, or salts thereof and croscarmellose sodium to increase the release rate; catechol-O-methyl transferase inhibitors |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | US20020131980 Comprises an immunizing amount of Mycoplasma hyopneumoniae bacterin, an adjuvant mixture comprising an acrylic acid polymer, a metabolizable oil, a polyoxyethylene polypropylene block copolymer, and an pharmaceutically acceptable carrier |
| 09/19/2002 | US20020131967 Such as melphalan and an anti-interleukin-6 receptor antibody, administering in synergistic amounts |
| 09/19/2002 | US20020131965 Conjugate of a bioactive agent covalently attached to a transport polymer, having guanidino or amidino side chains, such as an arginine-containing polypeptide |
| 09/19/2002 | DE10112768A1 New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases |
| 09/19/2002 | DE10112151A1 New 5-(4-(indolyl-alkyl)-piperazino)-benzofuran-2-carboxamides useful e.g. for treating depression, anxiety, psychiatric or cerebral disorders or pain, are 5-HT-1A receptor agonists and 5-HT reuptake inhibitors |
| 09/19/2002 | DE10110953A1 Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten Transdermal therapeutic system for administration of partial dopamine-D2 agonists |
| 09/19/2002 | DE10110754A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10058461A1 Substituierte Cyclohexanderivate und ihre Verwendung Substituted cyclohexane derivatives and their use |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2457234A1 Substituted tetracycline compounds as antifungal agents |
| 09/19/2002 | CA2441495A1 Proteins associated with cell growth, differentiation, and death |
| 09/19/2002 | CA2441177A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |